Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 14, 111-117

Helicobacter Pylori Therapy and Clinical Perspective

Affiliations
Review

Helicobacter Pylori Therapy and Clinical Perspective

Amin Talebi Bezmin Abadi et al. J Glob Antimicrob Resist.

Abstract

Helicobacter pylori induces chronic gastritis and duodenal ulcer in a small fraction of the colonised population. Three decades after the discovery of H. pylori and disclosure of an urgent need for eliminating the bacterium in patients, it seems that we are still in the first steps of dealing with this mysterious organism. Treatment of H. pylori is a complex dilemma for clinicians, a repeating sentence by many scientists who spend years on this research topic. Apart from many modifications in initial first-line treatment of H. pylori, gastroenterologists are unable to overcome the problem of therapeutic failure. Choosing the best regimen in any region depends on many factors, which have been the focus of many randomised clinical trials. A potential increase in efficacy of future therapies may be influenced by adding the novel potassium-competitive acid blocker vonoprazan. Undeniably, in-depth analysis is necessary to propose more effective therapeutic regimens. Meanwhile, we recommend the performance of antimicrobial susceptibility testing before any antimicrobial prescription.

Keywords: Antimicrobial resistance; Bacterial culture; Eradication rate; Helicobacter pylori.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

Substances

LinkOut - more resources

Feedback